Whalesbook
Novo Nordisk India mein apne two big drugs, Ozempic aur Wegovy, ke prices ko kaafi kam kar raha hai. Yeh strategy isliye banayi hai kyunki semaglutide (drug ka active ingredient) ka patent khatam ho gaya hai, aur ab Sun Pharma, Dr. Reddy's Laboratories, Zydus Lifesciences jaise bade Indian pharma companies saste generic versions launch kar rahe hain.
Price Cuts Ka Reason?
Ozempic ka price 36% tak kam kiya gaya hai, aur Wegovy ke starting dose par 48% tak ki cut lagi hai. Company ke Executive Vice-President, Emil Larsen, ne kaha ki India jaise price-sensitive market mein competitive rehna bahut zaroori hai, jahan weight-loss drugs ka demand abhi develop ho raha hai.
Brand Trust Aur Partnerships Par Focus
Larsen ne yeh bhi bataya ki crowded market hone ke bawajood, Novo Nordisk apni brand quality aur trust par focus karega. Unhone insulin products ka example diya, jahan patent expiry ke baad bhi unka brand name aur quality kaam aaya. Company ne Emcure Pharma Ltd. aur Abbott India Ltd. jaise partners ke saath bhi local tie-ups kiye hain taaki distribution network ka fayda utha saken.
Market Size Ek Challenge Hai
Larsen ne India mein weight-loss drug market ke kam size ko ek challenge aur opportunity bataya. Woh bole ki Denmark mein jitne patients hain, usse kam India mein hain, jo growth ki possibility dikhata hai. Company ko lagta hai ki ek strong brand, jo quality aur acche results ka history rakhta hai, agar reasonable price par mile toh emerging markets mein bahut effective ho sakta hai.